News
Treventis founders awarded funding for COVID-19 clinical trial
July 8, 2020
LifeArc, a major UK-based charity, has announced funding for Treventis founders Dr. Donald Weaver, Christopher Barden, and Mark Reed to…
Read More
Treventis attends Virtual BIO Conference
June 13, 2020
Not to be deterred by COVID-19, Treventis attended the BIO Digital International Convention (formerly scheduled for San Diego, California; instead…
Read More
Treventis attends 8th Neurodegenerative Drug Development Summit
February 25, 2020
Treventis CSO Mark Reed was in attendance at the 8th Neurodegenerative Drug Development Summit (previously known as World CNS) held…
Read More
Treventis Attends Tau2020 Conference
February 12, 2020
Treventis VP Research Marcia Taylor has attended Tau2020 in Washington, DC, which is one of the world’s biggest conferences focusing…
Read More
Treventis founders publish new computational methodology for brain drug design
December 13, 2019
Treventis founders Dr. Donald Weaver, Mark Reed, and Christopher Barden have supervised research at Toronto hospital UHN into new methods…
Read More
Treventis attends BioPort Atlantic Conference
November 6, 2019
Treventis CEO Christopher Barden attended BioPort, Atlantic Canada’s largest health and life sciences event in Halifax, Nova Scotia. BioPort is…
Read More
Treventis gives invites presentation at Texas Life Science Forum
November 6, 2019
Treventis CSO Mark Reed attended the Texas Life Science Forum on November 7th in Houston, Texas, an event that brought…
Read More
Treventis attends the 2nd Neuromuscular Drug Development Summit (NMD)
October 27, 2019
CEO Christopher Barden attended the NMD Summit in Boston, Massachusetts, where he spoke with therapeutic and diagnostic companies that are…
Read More
Treventis scientists visit Society for Neuroscience conference
October 24, 2019
Treventis was represented at the 50th Society for Neuroscience Conference in Chicago, Illinois, one of the world’s largest conferences dedicated…
Read More
Treventis CEO invited speaker, panelist at XV International Pharma Licensing Symposium
September 18, 2019
Treventis CEO Christopher Barden was honored to be an invited speaker at the XV International Pharma Licensing Symposium, running from…
Read More